Sotera Health Co financial statements

Income statement, balance sheet and cash flow statement for the last 7 fiscal years, taken from the XBRL data Sotera Health Co files with the SEC in its annual reports.

In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.

Income statement

	FY2019	FY2021	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	778	818	931	1,004	1,049	1,100	1,164
Cost of revenue	383	375	413	447	472	498	518
Gross profit	395	444	519	557	577	602	646
Selling, general and administrative	147	179	198	246	237	243	253
Operating expenses	212	238	262	309	300	305
Operating income	184	206	257	248	277	298
Other non-operating income	7.25	9.41	15.2	6.44	7.37	5.31	8.55
Pre-tax income	-0.92	-38.9	176	-243	106	114	148
Income tax	19.5	-1.37	58.6	-9.54	54.7	69.5	69.6
Net income to minority interests	0.43	1.13	0.24	0	0
Net income	-20.9	-38.6	117	-234	51.4	44.4	77.9
EBITDA	250	269	321	313	353	382
EPS, basic	-0.09	-0.16	0.41	-0.83	0.18	0.16	0.27
EPS, diluted	-0.09	-0.16	0.41	-0.83	0.18	0.16	0.27
Shares, basic (weighted)	232	238	279	280	281	283	284
Shares, diluted (weighted)	232	238	279	280	283	285	286

Balance sheet

	FY2019	FY2021	FY2021	FY2022	FY2023	FY2024	FY2025
Cash and equivalents	63	102	107	395	296	277	345
Receivables		91.7	108	118	148	140	139
Inventory		34.1	54.3	37.1	48.3	49.2	54.4
Other current assets		8.02	7.31	9.1	10.8	8.25	13.1
Total current assets		315	346	645	557	526	613
Property, plant and equipment		610	651	775	947	1,037	1,131
Lease right-of-use assets		46	39.9	26.5	24	27.6	33.4
Goodwill	1,036	1,116	1,120	1,102	1,111	1,081	1,103
Intangible assets		643	599	491	416	318	288
Other non-current assets		9.3	12.9	39	41.2	37.1	36.7
Total assets		2,761	2,790	3,118	3,130	3,072	3,263
Accounts payable		52.4	72.9	74.1	71	55.1	78
Accrued liabilities		60.5	61.9	490	122	90.5	125
Deferred revenue		6.06	8.67	12.1	13.5	15.1	18
Short-term debt		0	0	197	4.8	14.8	14
Total current liabilities		141	161	792	231	191	250
Long-term debt		1,825	1,744	1,747	2,224	2,208	2,127
Lease liabilities		38.9	33	21.6	20.1	24.5	29.9
Other non-current liabilities		17.5	16.3	12.8	8.88	4.42	7.36
Total liabilities		2,307	2,203	2,767	2,687	2,667	2,657
Total debt		1,825	1,744	1,944	2,228	2,223	2,141
Paid-in capital		1,166	1,173	1,190	1,215	1,244	1,262
Retained earnings		-589	-472	-706	-654	-610	-532
Treasury stock		-34	-33.5	-29.8	-27.2	-23.4	-17
Other comprehensive income		-93.8	-83.6	-107	-92.7	-208	-110
Shareholders' equity		452	586	350	444	405	606
Minority interests		2.27	0	0
Total equity	-641	455	586	350	444	405	606
Total liabilities and equity		2,761	2,790	3,118	3,130	3,072	3,263

Cash flow statement

	FY2019	FY2021	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	-20.4	-37.5	117	-234	51.4	44.4	77.9
Depreciation and amortization	66.7	63.3	64.2	64.3	76.6	84.3	94.9
Stock-based compensation	6.88	11	13.9	21.2	32.2	36.8	30.9
Deferred income tax	-19	-23.4	-3.72	-74	3.45	9.43	0.02
Change in receivables	11.8	1.94	-15.5	-12.6	-21.7	2.22	7.15
Change in inventory	-0.28	3.78	-20.2	14.4	-9.97	-4.75	-2.38
Change in payables	-8.97	-6.02	19.8	1.11	-5.33	-6.64	5.19
Cash from operations	149	121	282	278	-148	224	287
Capital expenditures	-57.3	-53.5	-102	-182	-215	-179	-138
Acquisitions	0	0	-13.5	0	0
Cash from investing	-57.3	-159	-160	-182	-215	-179	-135
Debt issued	3,145	150	0	200	500	2,259	0
Debt repaid	-2,561	-1,177	-100	0	-2.5	-2,264	-86.1
Stock issued	0	1,156	0	0
Share buybacks	0	-34	0	0
Dividends paid	-691	0	0
Cash from financing	-126	73.4	-117	198	266	-50.6	-101
Exchange rate effect	0.49	4.11	0.04	-4.46	2.04	-17.4	16.1
Net change in cash	-33.8	39.4	4.47	289	-94.6	-22.8	67.6
Free cash flow	91.8	67.1	179	95.6	-363	45.1	149
Interest paid	151	211	58.8	75.8	174	180	164
Income taxes paid	44.6	24	52	75.5	50.2	65.8	60.9

Key metrics

Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $18.34 on September 25, 2026.

Profitability

Metric	Value	How it is calculated
Gross margin	55.0%	Gross profit / revenue.
Pre-tax margin	21.7%	Pre-tax income / revenue.
Net margin	13.4%	Net income / revenue.
FCF margin	9.3%	Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin	24.0%	Cash from operations / revenue.
Effective tax rate	38.1%	Income tax / pre-tax income, when pre-tax income is positive.
Return on equity (ROE)	24.6%	Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)	4.9%	Net income / average total assets.
SG&A / revenue	21.1%	Selling, general and administrative expense / revenue.
Stock-based pay / revenue	3.1%	Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue	14.8%	Capital expenditures / revenue.
D&A / revenue	8.4%	Depreciation and amortization / revenue.

Growth

Metric	Value	How it is calculated
Revenue growth, 1y	5.7%	Revenue vs the same period a year earlier. Only from a positive base.
Revenue CAGR, 3y	5.1%	Compound annual growth of revenue over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Revenue CAGR, 5y	7.3%	Compound annual growth of revenue over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Gross profit growth, 1y	7.2%	Gross profit vs the same period a year earlier. Only from a positive base.
Gross profit CAGR, 3y	5.0%	Compound annual growth of gross profit over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Gross profit CAGR, 5y	7.8%	Compound annual growth of gross profit over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Net income growth, 1y	75.6%	Net income vs the same period a year earlier. Only from a positive base.
EPS growth, 1y	68.8%	EPS vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y	28.1%	Operating cash flow vs the same period a year earlier. Only from a positive base.
Operating cash flow CAGR, 3y	1.1%	Compound annual growth of operating cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Operating cash flow CAGR, 5y	19.0%	Compound annual growth of operating cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Free cash flow growth, 1y	230.8%	Free cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow CAGR, 3y	16.0%	Compound annual growth of free cash flow over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Free cash flow CAGR, 5y	17.3%	Compound annual growth of free cash flow over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Book value growth, 1y	49.7%	Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y	20.1%	Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y	6.0%	Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y	6.2%	Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y	1.5%	Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y	3.4%	Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y	0.5%	Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y	0.7%	Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y	3.8%	Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.

Balance sheet health

Metric	Value	How it is calculated
Current ratio	2.80x	Current assets / current liabilities.
Quick ratio	2.19x	(Cash + short-term investments + receivables) / current liabilities.
Cash ratio	1.54x	(Cash + short-term investments) / current liabilities.
Debt / equity	3.21x	Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets	64.7%	Total debt / total assets.
Liabilities / assets	79.9%	Total liabilities / total assets.
Net debt	$1.78B	Total debt - cash - short-term investments. Negative means more cash than debt.
Working capital	$415.2M	Current assets - current liabilities.
Goodwill and intangibles / assets	41.2%	(Goodwill + intangible assets) / total assets.
Tangible book value	-$695.8M	Shareholders' equity - goodwill - intangible assets.

Efficiency

Metric	Value	How it is calculated
Asset turnover	0.37x	Revenue / average total assets.
Fixed asset turnover	1.04x	Revenue / average property, plant and equipment.
Inventory turnover	9.72x	Cost of revenue / average inventory.
Days inventory	38 days	365 x average inventory / cost of revenue.
Receivables turnover	8.08x	Revenue / average receivables.
Days sales outstanding	45 days	365 x average receivables / revenue.
Days payables	67 days	365 x average accounts payable / cost of revenue.
Cash conversion cycle	15 days	Days inventory + days sales outstanding - days payables.
FCF conversion	68.9%	Free cash flow / net income, when net income is positive.
Capex / operating cash flow	61.4%	Capital expenditures / cash from operations, when that is positive.

Per share

Metric	Value	How it is calculated
EPS, diluted	$0.57	Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share	$4.22	Revenue / diluted weighted shares.
FCF per share	$0.39	Free cash flow / diluted weighted shares.
Operating cash flow per share	$1.01	Cash from operations / diluted weighted shares.
Book value per share	$2.31	Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Tangible book per share	-$2.41	Tangible book value / shares outstanding.
Cash per share	$1.24	(Cash + short-term investments) / shares outstanding.

Valuation

Metric	Value	How it is calculated
Market cap	$5.23B	Share price x shares outstanding.
Enterprise value	$7.02B	Market cap + total debt - cash - short-term investments.
P/E	32.0x	Market cap / net income. Only when net income is positive.
P/S	4.30x	Market cap / revenue.
P/B	7.86x	Market cap / shareholders' equity. Only when equity is positive.
P/FCF	46.4x	Market cap / free cash flow. Only when free cash flow is positive.
P/OCF	17.9x	Market cap / cash from operations, when positive.
EV/Sales	5.77x	Enterprise value / revenue.
EV/FCF	62.3x	Enterprise value / free cash flow, when both are positive.
FCF yield	2.2%	Free cash flow / market cap.
Earnings yield	3.1%	Net income / market cap (the inverse of P/E).

What was Sotera Health Co's revenue in fiscal 2025?

Sotera Health Co reported revenue of $1.16B for fiscal 2025, 5.7% higher than the year before.

Was Sotera Health Co profitable in fiscal 2025?

Yes. Net income was $77.9M, a net margin of 6.7%.

How much free cash flow did Sotera Health Co generate in fiscal 2025?

Cash from operations of $287.2M minus capital expenditures of $138.0M left free cash flow of $149.2M.

Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.

Open interactive statements, quarterly figures and charts

Back to Sotera Health Co